Related Party Transactions	6 Months Ended
Jun. 30, 2022
Related Party Transactions
Related Party Transactions	Note 8. Related Party Transactions Patagonia Patagonia is a private, family-owned company founded in 2013 to address the medical needs of people with rare and serious dermatological conditions. On February 28, 2019, and June 26, 2019, the Company acquired the TMB-001 and TMB-003 licenses from Patagonia (see Notes 3 and 9 for the payment terms and more details), respectively. Zachary Rome, a former member of the board of directors as well as the former Chief Operating Officer, Executive Vice-President and Secretary of the Company is also the President of Patagonia. As of June 30, 2022, and December 31, 2021, Patagonia owns 45 shares of the Company’s common stock. On March 4, 2022, Mr. Rome stepped down from his positions as Chief Operating Officer and Executive Vice-President of the Company. As a result of his resignation, Mr. Rome (i) was entitled to 79,326 shares of common stock underlying vested VARs, or $22,528, at the Company’s election, and (ii) forfeited 52,884 VARs. On March 4, 2022, Mr. Rome received 59,696 shares of common stock net upon exercise of the VARs after tax withholding. TardiMed The former Chairman of the Board of the Company is a Managing Member of TardiMed. Mr. Rome, a former member of the board of directors as well as the former Chief Operating Officer, Executive Vice President and Secretary is a partner at TardiMed. Our Chief Financial Officer, Treasurer, Secretary, and Executive Vice President of the Company was also a former partner of TardiMed. As of June 30, 2022, TardiMed holds 3,109,067 shares of common stock, which represents approximately 4.9% of the total voting shares outstanding. The Company had no reimbursements to TardiMed in the three and six-month periods ended June 30, 2022, and reimbursed TardiMed $63,936 for management fees and reimbursed expenses in the six-month period ended June 30, 2021. As of June 30, 2022, TardiMed holds 1,819 shares of Series A Preferred Stock (see Notes 5 and 9).

Related Party Transactions

6 Months Ended

Jun. 30, 2022

Note 8. Related Party Transactions

Patagonia

Patagonia is a private, family-owned company founded in 2013 to address the medical needs of people with rare and serious dermatological conditions. On February 28, 2019, and June 26, 2019, the Company acquired the TMB-001 and TMB-003 licenses from Patagonia (see Notes 3 and 9 for the payment terms and more details), respectively. Zachary Rome, a former member of the board of directors as well as the former Chief Operating Officer, Executive Vice-President and Secretary of the Company is also the President of Patagonia. As of June 30, 2022, and December 31, 2021, Patagonia owns 45 shares of the Company’s common stock.

On March 4, 2022, Mr. Rome stepped down from his positions as Chief Operating Officer and Executive Vice-President of the Company. As a result of his resignation, Mr. Rome (i) was entitled to 79,326 shares of common stock underlying vested VARs, or $22,528, at the Company’s election, and (ii) forfeited 52,884 VARs. On March 4, 2022, Mr. Rome received 59,696 shares of common stock net upon exercise of the VARs after tax withholding.

TardiMed

The former Chairman of the Board of the Company is a Managing Member of TardiMed. Mr. Rome, a former member of the board of directors as well as the former Chief Operating Officer, Executive Vice President and Secretary is a partner at TardiMed. Our Chief Financial Officer, Treasurer, Secretary, and Executive Vice President of the Company was also a former partner of TardiMed. As of June 30, 2022, TardiMed holds 3,109,067 shares of common stock, which represents approximately 4.9% of the total voting shares outstanding. The Company had no reimbursements to TardiMed in the three and six-month periods ended June 30, 2022, and reimbursed TardiMed $63,936 for management fees and reimbursed

expenses in the six-month period ended June 30, 2021. As of June 30, 2022, TardiMed holds 1,819 shares of Series A Preferred Stock (see Notes 5 and 9).